gemcitabine has been researched along with ginsenoside rh2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fagone, P; He, J; Li, Q; Li, S; Lu, Y; Nicoletti, F; Tian, C; Xiang, M; Yang, J; Yuan, H | 1 |
1 other study(ies) available for gemcitabine and ginsenoside rh2
| Article | Year |
|---|---|
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway.
Topics: Animals; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Dendritic Cells; Gemcitabine; Immunity; Mice; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |